BR0209020A - Composição farmacêutica de polialilamina - Google Patents

Composição farmacêutica de polialilamina

Info

Publication number
BR0209020A
BR0209020A BR0209020-1A BR0209020A BR0209020A BR 0209020 A BR0209020 A BR 0209020A BR 0209020 A BR0209020 A BR 0209020A BR 0209020 A BR0209020 A BR 0209020A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
polyallylamine
polymer
diluent
disclosed
Prior art date
Application number
BR0209020-1A
Other languages
English (en)
Inventor
John S Petersen
Steven Keith Burke
Stephen Randall Holmes-Farley
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of BR0209020A publication Critical patent/BR0209020A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA DE POLIALILAMINA". é descrita uma composição farmacêutica compreendendo um polímero de hidrocloreto de polialilamina estável na qual entre aproximadamente 4% a aproximadamente 12% por peso do polímero é um ânion cloreto e um transportador farmaceuticamente aceitável ou um diluente.
BR0209020-1A 2001-04-18 2002-04-10 Composição farmacêutica de polialilamina BR0209020A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28444501P 2001-04-18 2001-04-18
PCT/US2002/011408 WO2002085378A1 (en) 2001-04-18 2002-04-10 Low salt forms of polyallylamine

Publications (1)

Publication Number Publication Date
BR0209020A true BR0209020A (pt) 2004-08-10

Family

ID=23090248

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0209020-1A BR0209020A (pt) 2001-04-18 2002-04-10 Composição farmacêutica de polialilamina

Country Status (15)

Country Link
US (2) US7541024B2 (pt)
EP (1) EP1379258B1 (pt)
JP (2) JP5170932B2 (pt)
KR (1) KR20040018357A (pt)
CN (1) CN1290515C (pt)
AT (1) ATE331525T1 (pt)
AU (1) AU2002252632B2 (pt)
BR (1) BR0209020A (pt)
CA (1) CA2444587C (pt)
DE (1) DE60212819T2 (pt)
ES (1) ES2268013T3 (pt)
MX (1) MXPA03009572A (pt)
NZ (1) NZ528829A (pt)
WO (1) WO2002085378A1 (pt)
ZA (2) ZA200308063B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
AU2003282867A1 (en) * 2002-10-22 2004-05-13 Genzyme Corporation Amine polymers for promoting bone formation
AU2003263010A1 (en) * 2003-09-02 2005-04-21 Genzyme Corporation Method for reducing vascular inflammation
EP2158902B1 (en) 2004-03-30 2017-12-06 Relypsa, Inc. Ion binding compositions and their use
US7985418B2 (en) 2004-11-01 2011-07-26 Genzyme Corporation Aliphatic amine polymer salts for tableting
US20060177415A1 (en) * 2004-11-01 2006-08-10 Burke Steven K Once a day formulation for phosphate binders
JP2009507019A (ja) 2005-09-02 2009-02-19 ジェンザイム・コーポレーション リン酸塩を除去する方法およびそれに使用される重合体
WO2007035313A2 (en) 2005-09-15 2007-03-29 Genzyme Corporation Sachet formulation for amine polymers
JP2009542653A (ja) * 2006-07-05 2009-12-03 ジェンザイム コーポレーション リン酸塩過剰血症のための鉄（ｉｉ）含有治療剤
WO2008042222A2 (en) 2006-09-29 2008-04-10 Genzyme Corporation Amide dendrimer compositions
EP2120972A1 (en) 2006-12-14 2009-11-25 Genzyme Corporation Amido-amine polymer compositions
EP2016947A1 (en) 2007-07-17 2009-01-21 Chemo Ibérica, S.A. Novel one step process for preparing cross-linked poly(allylamine) polymers
US20100331516A1 (en) * 2008-04-08 2010-12-30 Govind Dhananjay Sathe Process for Preparation of Sevelamer Carbonate
US8404784B2 (en) * 2008-12-03 2013-03-26 Navinta Llc Manufacturing process of making polymeric amine salts
BRPI1012076A2 (pt) * 2009-06-16 2019-04-16 Watson Pharma Private Ltd processos para preparação de carbonato de sevelamer
BR112012021444A2 (pt) * 2010-02-24 2016-05-31 Relypsa Inc polímero de amina reticulado, composição farmacêutica, método de redução do colesterol ldl sérico em um indivíduo, métodos para tratar doença, de remoção de sais biliares de um indivíduo, e para melhorar o controle glicêmico em um indivíduo, e, processo para preparar o polímero de aminas.
ES2834485T3 (es) * 2013-06-05 2021-06-17 Tricida Inc Polímeros de unión a protones para administración oral
MA41150B1 (fr) 2014-12-10 2020-06-30 Tricida Inc Polymères de liaison aux protons pour administration orale
MA44875A (fr) 2016-05-06 2019-03-13 Tricida Inc Compositions pour le traitement de troubles acido-basiques
BR112019013364A2 (pt) 2016-12-28 2020-04-14 Fujifilm Corp emulsão de polímero contendo átomo de nitrogênio ou sal do mesmo, método de produção para o mesmo e método de produção para partículas
EP3698798A4 (en) 2017-10-16 2020-12-23 FUJIFILM Corporation THERAPEUTIC AGENT AGAINST HYPERPHOSPHATEEMIA, AND PARTICLES
TW201922267A (zh) 2017-10-16 2019-06-16 日商富士軟片股份有限公司 高磷血症治療劑
IL273960B2 (en) 2017-11-03 2025-08-01 Tricida Inc Nonabsorable compositions for use in treating or preventing metabolic acidosis
CN110753217B (zh) * 2019-10-28 2022-03-01 黑芝麻智能科技(上海)有限公司 色彩平衡方法和装置、车载设备以及存储介质
US11572355B2 (en) * 2020-07-16 2023-02-07 The Board Of Trustees Of The University Of Alabama Methods for synthesizing vinylidenes and alkenes
CN112047854B (zh) * 2020-10-20 2021-07-02 中国科学院长春应用化学研究所 一种n-乙烯基烷基酰胺的制备方法
EP4164659B1 (en) * 2021-08-24 2024-03-27 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Polymers, compositions and methods for treating hyperuricemia
EP4161534B1 (en) 2021-08-24 2024-11-06 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Polymers, compositions and methods for treating hyperuricemia

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4222921A (en) * 1978-06-19 1980-09-16 Monsanto Company Polyamine/epihalohydrin reaction products
JPS6090243A (ja) * 1983-10-25 1985-05-21 Nitto Boseki Co Ltd 小球状モノアリルアミン橋かけ重合体の製造方法
US4528347A (en) * 1983-11-10 1985-07-09 501 Nitto Boseki, Co. Ltd Process for producing polymers of monoallylamine
US4614593A (en) * 1985-03-28 1986-09-30 Ethyl Corporation Demulsification of oil-in-water emulsions
IE914179A1 (en) * 1990-12-07 1992-06-17 Ici Plc Nitrogen derivatives
US5487888A (en) * 1993-05-20 1996-01-30 Geltex, Inc. Iron-binding polymers for oral administration
US5607669A (en) * 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
US5618530A (en) * 1994-06-10 1997-04-08 Geltex Pharmaceuticals, Inc. Hydrophobic amine polymer sequestrant and method of cholesterol depletion
US5703188A (en) * 1993-06-02 1997-12-30 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US5624963A (en) * 1993-06-02 1997-04-29 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US5900475A (en) * 1994-06-10 1999-05-04 Geltex Pharmaceuticals, Inc. Hydrophobic sequestrant for cholesterol depletion
US5496545A (en) * 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5667775A (en) * 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
TW474813B (en) * 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
WO1996021454A1 (en) * 1995-01-12 1996-07-18 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US6203785B1 (en) * 1996-12-30 2001-03-20 Geltex Pharmaceuticals, Inc. Poly(diallylamine)-based bile acid sequestrants
US5925379A (en) * 1997-03-27 1999-07-20 Geltex Pharmaceuticals, Inc. Interpenetrating polymer networks for sequestration of bile acids
JP2003183168A (ja) * 1997-04-04 2003-07-03 Chugai Pharmaceut Co Ltd リン酸結合性ポリマー含有製剤
TW592727B (en) 1997-04-04 2004-06-21 Chugai Pharmaceutical Co Ltd Phosphate-binding polymer preparations
US6423754B1 (en) * 1997-06-18 2002-07-23 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with polyallylamine polymers
US5985938A (en) * 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
US6083497A (en) * 1997-11-05 2000-07-04 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
US6726905B1 (en) 1997-11-05 2004-04-27 Genzyme Corporation Poly (diallylamines)-based phosphate binders
AU2682499A (en) 1998-02-17 1999-08-30 Dimitri R. Kioussis Anion binding polymers and the use thereof
TW568788B (en) * 1998-10-12 2004-01-01 Chugai Pharmaceutical Co Ltd Polymer combining with phosphoric acid and preparation containing the same
US6180754B1 (en) * 1999-09-03 2001-01-30 The Dow Chemical Company Process for producing cross-linked polyallylamine polymer
US6733780B1 (en) * 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core

Also Published As

Publication number Publication date
US7541024B2 (en) 2009-06-02
HK1058620A1 (en) 2004-05-28
DE60212819T2 (de) 2006-11-23
JP2010111704A (ja) 2010-05-20
ES2268013T3 (es) 2007-03-16
NZ528829A (en) 2006-06-30
DE60212819D1 (de) 2006-08-10
EP1379258A1 (en) 2004-01-14
KR20040018357A (ko) 2004-03-03
ZA200308065B (en) 2004-09-14
CA2444587A1 (en) 2002-10-31
ATE331525T1 (de) 2006-07-15
CN1290515C (zh) 2006-12-20
US20100068167A1 (en) 2010-03-18
WO2002085378A1 (en) 2002-10-31
JP5243466B2 (ja) 2013-07-24
US20020159968A1 (en) 2002-10-31
EP1379258B1 (en) 2006-06-28
CN1503676A (zh) 2004-06-09
US8377428B2 (en) 2013-02-19
AU2002252632B2 (en) 2004-09-23
ZA200308063B (en) 2005-01-17
JP5170932B2 (ja) 2013-03-27
CA2444587C (en) 2008-10-21
JP2004526777A (ja) 2004-09-02
MXPA03009572A (es) 2004-02-12

Similar Documents

Publication Publication Date Title
BR0209020A (pt) Composição farmacêutica de polialilamina
PL350456A1 (en) N−cyanomethylamides as protease inhibitors
SE0300010D0 (sv) Novel Compounds
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
LU92853I2 (fr) Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégée par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine et l'emtricitabine
DE602004024375D1 (de) Carboxamidderivate
LU92315I2 (fr) Combinaison comprenant aliskiren, ou un de ses sels pharmaceutiquement acceptable, et amlodipine, ouun de ses sels pharmaceutiquement acceptable
PT1073470E (pt) Composicoes farmaceuticas contendo compostos com actividade capaz de melhorar a absorcao de ingredientes activos
IL192937A0 (en) Pharmaceutical compositions containing beta-lapachone or derivatives or analogs thereof, and methods of using same
MXPA05007609A (es) Antagonista de un receptor sensible al calcio.
SE0101932D0 (sv) Pharmaceutical combinations
TNSN04034A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
ATE303384T1 (de) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
SE9802208D0 (sv) Novel compounds
BR0012696A (pt) Composição oftálmica
SE0102440D0 (sv) New compound
SE0102055D0 (sv) New Compounds
WO2003053971A8 (en) Pyridoquinoxaline antivirals
WO2002067865A3 (en) N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof
AU2001290480A1 (en) Cyclized benzamide neurokinin antagonists for use in therapy
MXPA04001419A (es) Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson.
SE9802209D0 (sv) Novel compounds
SE0001916D0 (sv) Novel formulation
TW200510370A (en) Urea derivatives
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: GENZYME CORPORATION (US)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 018080029522/SP DE 14/05/2008.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A E 7A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2029 DE 24/11/2009.